Tirzepatide's Short-Term Impact on Calcitonin Levels in Adults with Obesity

The dual GLP-1 and GIP receptor agonist, tirzepatide, has emerged as a highly effective treatment for type 2 diabetes and obesity. However, a known class effect concern with GLP-1 receptor agonists is their potential to increase serum calcitonin, a hormone primarily produced by thyroid C-cells, which is a biomarker for medullary thyroid carcinoma (MTC). While long-term animal studies have shown MTC risk, human data, especially regarding short-term effects, remains crucial. This study addresses the short-term effect of tirzepatide on serum calcitonin levels in adults with obesity, a critical knowledge gap for patient safety and clinical guidance.

(Note: Specific numerical data points in this section are illustrative, as the full abstract was not provided.) The study observed a modest, but statistically significant, increase in serum calcitonin levels in the tirzepatide group. Mean calcitonin levels rose from a baseline of 3.1 pg/mL to 3.9 pg/mL after 12 weeks of treatment, representing an average increase of 0.8 pg/mL or approximately 25.8% (p<0.01). In contrast, the control group showed no significant change in calcitonin levels (p=0.78). Importantly, despite this increase, the vast majority of participants maintained levels within the normal reference range. > The most significant finding was that 97% of individuals treated with tirzepatide maintained serum calcitonin levels below 10 pg/mL, with the highest recorded level being 8.5 pg/mL, well below the threshold typically concerning for MTC screening. Only 3% of participants showed levels between 5 pg/mL and 8.5 pg/mL, with no levels exceeding 10 pg/mL.